•SAP is acquiring German AI startup Prior Labs and investing €1 billion ($1.16B) over four years to establish an AI lab focused on tabular foundation models (TFMs) for structured enterprise data.
•The move aims to accelerate AI penetration in enterprise business processes, leveraging TFMs as a more suitable AI approach for SAP's core financial, HR, and procurement data than large language model...
•SAP has also updated its API policy to block unauthorized AI agents like OpenClaw, allowing only 'SAP-endorsed architectures' such as its own Joule Agents and Nvidia's NemoClaw, for controlled, secure...
•Artificial intelligence is rapidly accelerating the generation of novel drug candidates, creating an unprecedented volume of potential molecules for research.
•The emerging challenge for pharmaceutical R&D is no longer just generating candidates, but efficiently sifting through this 'drug flood' to identify truly promising compounds.
•A new startup is focused on leveraging advanced analytics and AI to pinpoint the most viable drug candidates from this immense output, streamlining early-stage discovery.
•SAP is acquiring German AI startup Prior Labs and investing €1 billion ($1.16B) over four years to establish an AI lab focused on tabular foundation models (TFMs) for structured enterprise data.
•The move aims to accelerate AI penetration in enterprise business processes, leveraging TFMs as a more suitable AI approach for SAP's core financial, HR, and procurement data than large language model...
•SAP has also updated its API policy to block unauthorized AI agents like OpenClaw, allowing only 'SAP-endorsed architectures' such as its own Joule Agents and Nvidia's NemoClaw, for controlled, secure...
•Artificial intelligence is rapidly accelerating the generation of novel drug candidates, creating an unprecedented volume of potential molecules for research.
•The emerging challenge for pharmaceutical R&D is no longer just generating candidates, but efficiently sifting through this 'drug flood' to identify truly promising compounds.
•A new startup is focused on leveraging advanced analytics and AI to pinpoint the most viable drug candidates from this immense output, streamlining early-stage discovery.